Purpose: To assess the acceptance, long term efficacy and preference of Sildenafil in impotent patients previously on auto-intracavernosal therapy. Material and methods: The patients were the 107 men (mean age 58.4 y) on auto-intracavernosal therapy (auto-IC) for more than 6 months (mean duration 32.7 months > 12 months in 100) who were consecutively seen within 6 months of the launch of Sildenafil in France. If there was no contra-indications to Sildenafil they were proposed a trial of Sildenafil at home. Following this trial they were given the possibility to change their therapy and were followed for 1 y at 3 months intervals. Results: Three patients had contra-indications to Sildenafil. Of the remaining 104, 45 (43%) refused the trial, mainly because they were afraid of possible cardiac risks (n ¼ 21, including 51% of the psychogenic and mixed patients compared to 8% of the predominantly organic ones). Among the 59 who tried it, Sildenafil gave good results in 46 (78%), including 100% of the predominantly psychogenic and 61.5% of the predominantly organic ones) with minimum effective doses of 25 mg in 7, 50 mg in 18 and 100 mg in 21. It failed in 9 (15%) and gave average results in 4 (penetration with a non fully satisfying erection). There was a clear relationship between the sensitivity to Sildenafil and that to Alprostadil, the vasoactive agent predominantly used for the auto-ICIs. Every 46 patients with good result of Sildenafil elected to continue with this drug, including 3 who used both Sildenafil and auto-ICIs in alternance. Every 4 patients with average results elected to continue with auto-ICI including 1 who also used Sildenafil in alternance. Five of the 50 patients with good or average results were lost to follow-up within 6 months. At the 1 y follow-up visit, 43 of the 45 others were still using Sildenafil, in alternance with auto-ICI in 1. No one reported a decrease in efficacy with time. The 2 patients with average results still in the study were on auto-ICIs. Conclusion: Sildenafil is highly effective in the impotent men previously treated with auto-ICI and its efficacy is maintained at least for 1 y. When tried and effective it is preferred by most men but almost half of our patients refused trying it.
Sildenafil has revolutionized the treatment of erectile dysfunction and is now considered as the first option in this field. 1 However this treatment is not accepted by every patient, and it may be less effective than the intracavernosal injections of vaso-active agents (ICI). In this study, we intended assessing the acceptance and efficacy of Sildenafil in a particular category of patients, those previously on long term auto-intracavernosal therapy (auto-ICI). In addition we assessed the adherence to Sildenafil treatment, and the results at 1 y in the patients who changed for this drug.
Materials and methods
The patients were the 107 impotent males on auto-ICI therapy since at least 6 months (more than 12 months in 100) who were consecutively seen in our center for regular follow-up within 6 months of the launch of Sildenafil (Viagra 1 ) in France (October 1998). They were 35 to 70 y old (mean 58.4) with a mean duration of auto-ICI therapy of 32.7 months. According to medical and sexual history, as well as to the results of the tests performed before starting auto-ICIs, the etiology of erectile dysfunction was considered as predominantly psychogenic in 41, predominantly organic in 38 and mixed in 28. The main potential organic factors identified in the 2 last categories were diabetes in 10, vascular or tissular in 58, and neurological in 15 (several factors were associated in 17). The vaso-active agents used for the injections were Alprostadil alone (PGE1) in 83, bimix (PGE1 þ Phentolamine), or trimix (PGE1 þ Phentolamine þ Papaverine) in 21 (we use these associations only in the case of failure of PGE1 alone) and Moxisylyte in 3.
The study design included 5 phases: I. Checking for contra-indications to Sildenafil. The following were considered as exclusion criteria: recent (< 6 months) myocardial infarction or stroke, unstable angina, retinitis pigmentosa, treatment with nitrates or Nitric Oxyde donors (Linsidomine, Nicorandil).
II. In the case there were no contra-indications proposing to the patients a trial of Sildenafil at home after detailed information on the effectiveness, expected adverse events, and safety of this treatment. Because our study started only a few months after the mediatic turmoil which followed the announcement of several fatalities in american men on Viagra 1 , many men and=or female partners expressed important concerns regarding possible cardiac risks of this medication. These were given more details on the absence of significant difference in the rates of deaths as well as of the different types of cardiovascular events in the patients on Sildenafil with respect to those on placebo in the preregistration double blind placebo controlled studies. 2 The persistance of the Food and Drug Administration, and later of the corresponding french ''Agence du Médicament'', in their official opinion that Sildenafil was safe on condition of respecting its specific contra-indications were also commented.
III. The patients who accepted the trial were proposed to start with the dose of 50 mg, or 25 mg if they were more than 65 y old, if they had significant hepatic or renal insufficiency (one case in this study), or if they remained afraid of the possible cardiac risks. The tablet was taken 1 hour before an anticipated attempt of intercourse, having avoided to take previously a fatty meal, or more than one glass of alcoholic drink. The requirement of a sexual stimulation to induce erection, on the contrary of following the ICI, was emphasized to them. The dose was then gradually increased up to 100 mg in case the previous step had failed at least twice to result in an erection allowing penetration and a satisfying intercourse. A good result was defined by an erection adequate for penetration and satisfactory sexual intercourse, an average result as the possibility of penetration followed by a non fully satisfactory intercourse due to insufficient rigidity or duration, and a failure of Sildenafil as the failure of at least 2 attempts with the dose of 100 mg.
IV. Following the initial trial, the patients able to penetrate on Sildenafil were proposed to change their treatment for this drug. On request they were allowed to use both treatments in alternance, on condition of leaving an interval of at least 24 h between using Sildenafil and injecting themselves and vice versa.
V. The patients who decided to continue with Sildenafil were then followed up at 3 months intervals for one year in order to assess the long term results and tolerance of this drug, as well as the final preference of the patients.
Results
Three (2.8%) of the 107 impotent patients on longterm auto-ICI had contra-indications to this drug (all 3 were taking nitrates for coronary heart disease). Among the 104 presenting no contra-indication 45 (43%) refused the trial and 59 (57%) accepted it. The proportion of those who refused was higher in case of psychogenic contribution to erectile dysfunction (predominantly psychogenic group 15=40: 37.5%, mixed group 19=27: 70%, predominantly organic 11=37: 30%). The main reason alleged for refusing the trial was the fear of possible risks of Sildenafil despite our detailed information, essentially cardiac risks (n ¼ 21: 20% of all the patients who were proposed the trial, including 8 of the predominantly psychogenic [20% of this category], 10 of the mixed [37%] and only 3 of the predominantly organic cases [8%]). Eighteen other patients (17%) alleged they did not have any reason for changing since they were fully satisfied with the auto-ICI (psychogenic: 5=40: 12%, mixed: 7=27: 26%, organic: 6=37: 11%). It seemed to us that in some of these cases the fear of possible risks might in fact be the real underlying reason. Four of the patients mainly alleged the longer time to erection with Sildenafil compared to ICI. Lastly 2 alleged the cost of Sildenafil. In this study, they had to pay for their medications. Both were on triple mix and used a low dose of PGE1, resulting in a lower cost of the injections with respect to Sildenafil.
The results of the Sildenafil trial are listed in Table 1 . Overall 78% of the patients reported good results and 7% average results, while Sildenafil totally failed in 15%. All the predominantly psychogenic patients had good results (100%) while the rate of total failures was higher in the mixed (12.5%) and predominantly organic (31%) groups. The highest failure rate was in the small subgroup of the 7 diabetic patients. In the 46 cases reporting good results with Sildenafil, the minimum effective dose was 25 mg in 7 (15%), 50 mg in 18 (39%) and There was clearly a relationship between the success of Sildenafil and the sensitivity of the patients to ICI. Sildenafil failed in only 1 of the 29 patients requiring 10 mg or less of PGE1, compared to 23% of the patients requiring 20 mg of PGE1 and 4=6, 67%, of those only sensitive to Triple mixture 2. All the 7 patients responding to the low dose of 25 mg were sensitive to a low or medium dose of PGE1 (10 mg or less).
Following the trial, all the 46 patients with good results elected to continue Sildenafil including 3 who requested to use both treatments in alternance. Three of the 4 patients with average results elected to stay on auto-ICI, while the fourth started to use both treatments in alternance. Figure 1 shows the preference of these 50 preceding patients at the different stages of the study. Five patients were lost to follow-up (2 at 3 months and 3 at 6 months), including 2 of the 4 patients with average results. After 12 months 2 of 45 patients (4%) were on auto-ICI (the 2 patients with average results of Sildenafil still in the study), only 1 was still using both types of therapies (2%), and 42=45 were using only Sildenafil. No one patient reported a decrease in the efficacy of this drug with time.
Overall 22 of the 104 patients (21%) reported at least 1 side effect following the use of Sildenafil. These included headache in 10, flushing in 10, dyspepsia in 5, nasal congestion in 2 and visual changes in 2 (blue haze in 1 and an increase of brightness in 1). All these side effects were mild to moderate in intensity and transient in duration (limited to 1 to 24 hours following the intake of a tablet). No one led to permanent discontinuation of the treatment.
Discussion
Our study confirms that Sildenafil is highly effective in the impotent patients treated with auto-ICI before Sildenafil in men on auto-ICI therapy J Buvat et al the launch of this oral therapy. Our success rate of 78% fits well with those of 75% in the patients of Hatzichristou et al, 3 70% in these of McMahon et al 4 and 69% in these of Giuliano et al. 5 In our patients the success rate was clearly higher in the subgroup with psychogenic impotence than in that with predominantly organic origin. As Hatzichristou et al, 3 we found an inverse relationship between the effectiveness of Sildenafil and the dose of vasoactive agents required for the effectiveness of the auto-ICI therapy, ie higher was the dose of the auto-ICI or the strength of the mixture required, lower was the success rate of Sildenafil. The rate of the adverse events was close to that reported in unselected populations treated with Sildenafil, and lower than that of the patients previously on auto-ICI of Hatzichristou et al. 3 All the adverse events were mild or moderate, and transient in nature. In our series all the patients who tried Sildenafil and obtained good results elected to continue with this drug. This rate of 100% was higher than the 61% reported by Hatzichristou et al 3 and the 48.5% reported by Mac Mahon et al. 4 Eight percent of our patients elected to continue with both drugs. The corresponding figures were respectively of 7% and 32% in the studies by Hatzichristou et al and Mac Mahon et al. As in the study by Hatzichristou 3 this rate decreased with time with only 1 patient still using both drugs after 1 y in our study.
One of the original aspects of our study is the 12 months follow-up. The effectiveness and tolerance to Sildenafil remained stable all this time. All the patients remained on Sildenafil, except 2 having obtained only average results. This very high continuation rate may seem amazing because of the one hour time interval between dosing and intercourse in patients previously used to auto-ICI, with a much shorter interval. In fact it confirms the high motivation of these men having previously regularly used auto-ICI therapy for almost 3 y in average, and how a pill meets the needs of the ED patients much more than auto-ICI therapy.
The other original aspect of this study is the very high rate of patients having refused the trial of Sildenafil (43%). This rate of refusal was not reported in the other studies. The main reason alleged for refusing it was the fear of possible cardiac risks of this drug. This fear resulted from the many papers published in the lay-press which had exaggerated these risks following the report of fatalities in american men supposed to have used Sildenafil. In fact this fear of using Sildenafil is still persisting in 2002 in many french patients with ED, or in their partners, although after more than 11 000 patients years of observations in clinical trials, and prescription to more than 10 millions patients worldwide, there is no evidence to support this drug as a cause of serious cardiovascular effects, including myocardial infarction and death. 2, 6 Nevertheless the cardiac risk associated with sexual activity must be the first consideration before advising patients with known or possible cardiovascular disease to resume having sex, or before initiating any therapy for erectile dysfunction. Likewise the association with nitrates or nitric oxide donors must be definitively contra-indicated.
Conclusions
The high efficacy and preference rates of Sildenafil in men with erectile dysfunction previously on auto-ICI confirms its place as first line treatment for erectile dysfunction of various etiologies. Nevertheless the fact that Sildenafil failed in some men successfully treated with auto-ICI shows that every patients should be informed about the potential effectiveness of this second therapy in case of failure of Sildenafil. Success rates of 33% 4 to 88% 7 have been reported with injection therapy in patients refractory to Sildenafil.
Our study also stresses the frequent concerns of the couple regarding the cardiac safety of Sildenafil. These are not always clearly expressed and are at the origin of one of the main psychological resistances to this pharmacological therapy. A brief review of the safety data likely to reassure them should be considered before any prescription of this drug.
